Optical Preclinical Imaging Market by Modality and End User : Global Opportunity Analysis and Industry Forecast, 2021–2030

Optical Preclinical Imaging Market by Modality and End User : Global Opportunity Analysis and Industry Forecast, 2021–2030

  • November 2021 •
  • 185 pages •
  • Report ID: 6223756 •
  • Format: PDF
Optical Preclinical Imaging Market by Modality (Bioluminescence & Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems, and Optical + X-ray & Optical + CT) and End User (Pharma & Biotech Companies, Academic & Government Research Institutes, and Contract Research Organizations): Global Opportunity Analysis and Industry Forecast, 2021–2030

The global optical preclinical imaging market was valued at $516.10 million in 2020, and is estimated to reach $859.70 million by 2030, growing at a CAGR of 5.2% from 2021 to 2030. Optical preclinical imaging is the visualization of living animals for research purposes, such as drug discovery and development. Imaging modalities have often been important to researchers in monitoring changes in animals responding to physiological or environmental changes, whether at the organ, tissue, cell, or molecular level. Noninvasive and in vivo imaging methods have grown more relevant for studying animal models over time.
Optical imaging can monitor disease progression and evaluate effects of drug candidates with extremely high sensitivity. Preclinical imaging is essential for phenotyping, drug development, and providing a fundamental knowledge of disease mechanisms. The major objective is to enhance the probability of clinical success while shortening the time and expense of drug research and development. Translational research is transforming current medicine and the way health problems are handled and solved. The use of small-animal models in fundamental and preclinical sciences is a critical component of these types of research and development initiatives, serving as a link between molecular discoveries and clinical implementation in diagnostics and therapeutics.
Preclinical imaging encompasses a range of modalities, and can be broadly classified as predominantly morphological/anatomical imaging approaches or molecular imaging techniques. For anatomical imaging, techniques such as high-frequency micro-ultrasound, magnetic resonance imaging (MRI), and computed tomography (CT) are commonly used, whereas optical imaging (fluorescence and bioluminescence), positron emission tomography (PET), and single photon emission computed tomography (SPECT) are used for molecular visualizations. Each modality has advantages and disadvantages. Recently, multimodality devices have been designed such as SPECT/CT to give complementary information on the pathophysiological processes.
High-resolution modalities exhibit the ability to noninvasively image and monitor molecular processes within tumors, molecular imaging represents a fundamental tool for cancer scientists. The combination of high-resolution modalities such as micro-CT or micro-MRI, with highly sensitive techniques that provide functional information, such as micro-PET or micro-SPECT, continue to broaden the horizons of research in key areas such as infection, oncology, cardiology, and neurology, contributing not only for a better understanding of disease mechanisms but also for providing efficient and unique tools to evaluate new chemical entities and candidate drugs. For instance, in 2019, Kawasaki Medical University, Yokohama’s research hub for state-of-the-art medical science and services installed an ultrahigh-resolution E-Class U-SPECT6/CT system for preclinical imaging. It is the only nuclear imaging system that can image mice with the same visual acuity as can be obtained from imaging humans with clinical scanners.
Increase in the use of optical preclinical imaging is majorly due to technological advancements in molecular imaging, surge in demand for noninvasive small animal imaging techniques, and rise in preclinical research funding, by both private and public organizations. In addition, the outbreak of new diseases and personalization of treatments have led to various drug developments, which, in turn, leads to clinical trials. Optical preclinical imaging is utilized to monitor therapy response for early efficacy indications. Technological advancements in vivo imaging enables quantitative research of diseases at the molecular level.
According to the USFDA in 2021, about 42 new molecular entities and new therapeutic biological products have been approved by the Center for Drug Evaluation and Research (CDER). Moreover, optical imaging assists in the diagnosis of precise tissue or organ malfunctioning and thus targeted therapies can be provided according to the genetic make-up of each individual patient, resulting in treatment personalization depending on their specific requirement. Furthermore, in September 2020, Pharmaceutical Research and Manufacturers of America (PhRMA) member companies invested $83 billion in research and development (R&D) in 2019, and over the past two decades, PhRMA member companies have invested a total of nearly $1 trillion in the search for and development of new and better treatments and cures. Thus, the aforementioned factors are anticipated to notably contribute toward the growth of the global market.
In vivo imaging serves as a link between in vitro exploratory and in vivo clinical research, thus facilitating direct and rapid transfer of preclinical investigations on animal models to clinical trials in humans. Cancer, autoimmune illnesses, neurological disorders, and cardiovascular diseases are the primary disease areas targeted by in vivo preclinical imaging. However, high installation and operational cost and stringent regulatory guidelines for preclinical research and restriction on animal testing restrain the market growth.
The global optical preclinical imaging market is segmented into modality, end user, and region. On the basis of modality, the market is segregated into bioluminescence & fluorescence imaging systems, standalone fluorescence imaging systems, and optical + X-ray & optical + CT. By end user, it is fragmented into pharma & biotech companies, academic & government research institutes and contract research organizations.

The major players profiled in the report are Berthold Technologies GmbH & Co.KG, Endress+Hauser (Analytik Jena US LLC), Fujifilm Corporation (Fujifilm VisualSonics Inc.), LI-COR Biosciences, Inc., Miltenyi Biotec B.V. & CO. KG, PerkinElmer, Inc., Rigaku Corporation (MILabs B.V.), TriFoil Imaging, Vieworks Co., Ltd., and Vilber Smart Imaging Ltd.

• This report provides an extensive analysis of the current and emerging market trends and dynamics in the global medical simulation market to identify the prevailing opportunities.
• This study presents the competitive landscape of the global market to predict the competitive environment across geographies.
• Comprehensive analysis of factors that drive and restrict the market growth is provided.
• Region- & country-wise analysis is provided to understand the market trends and dynamics.


By Modality
o Bioluminescence & fluorescence imaging systems
o Standalone fluorescence imaging systems
o Optical + x-ray & optical + CT

By End User
o Pharma and biotech companies
o Academic & government research institutes
o Contract research organizations

By Region
o North America
- U.S.
- Canada
- Mexico
o Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
o Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Latin America
- Middle East & Africa

• Berthold Technologies GmbH & Co.KG
• Endress+Hauser (Analytik Jena US LLC)
• Fujifilm Corporation (Fujifilm VisualSonics Inc.)
• LI-COR Biosciences, Inc.
• Miltenyi Biotec
• PerkinElmer, Inc.
• Rigaku Corporation (MILabs B.V.)
• TriFoil Imaging
• Vieworks Co., Ltd.
• Vilber Smart Imaging Ltd